Epigen vs Survodutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Epigen
Epigen is a member of the epidermal growth factor (EGF) family. It plays roles in skin regeneration and has been studied for wound healing and anti-aging applications.
Full details →Survodutide
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It is being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and obesity. Survodutide's glucagon receptor activation promotes hepatic fat mobilization, making it uniquely suited for liver-related metabolic conditions.
Full details →Side-by-Side Comparison
| Aspect | Epigen | Survodutide |
|---|---|---|
| Mechanism | Binds to and activates the EGF receptor (EGFR), promoting cell proliferation, migration, and differentiation. Involved in skin homeostasis and repair processes. | Survodutide activates both GLP-1 and glucagon receptors. The GLP-1 component provides appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying. The glucagon component drives hepatic fat oxidation, increases energy expenditure, and promotes lipolysis. This dual mechanism is particularly effective for MASH, where hepatic fat accumulation is the core pathology. Unlike tirzepatide (which targets GIP/GLP-1), survodutide targets glucagon/GLP-1 — a different receptor combination optimized for liver and metabolic outcomes. |
| Typical Dosage | Topical: Typically used at low concentrations (ppm to low %) in cosmetic formulations. Research applications vary. | Phase 2 MASH trial: escalated to 2.4 mg, 4.8 mg, or 6.0 mg weekly. Phase 2b obesity trial: up to 6.0 mg weekly. Dose escalation over 16-20 weeks to manage GI tolerability. Final approved dosing not yet established — Phase 3 trials ongoing. |
| Administration | Primarily topical application for skincare. Research may use other routes for systemic effects. | Subcutaneous injection, once weekly. Phase 3 trials use pre-filled pens. Not yet commercially available. Phase 3 results expected 2026-2027. |
| Side Effects | Topical use generally well-tolerated. Theoretical concerns about promoting cell proliferation. | Phase 2 data: nausea, vomiting, diarrhea (dose-dependent, generally transient). Reduced appetite. Transient increases in heart rate. The GI side effect profile appears similar to other GLP-1 agonists. |
| Best For |
Key Differences
Unique to Epigen:
Unique to Survodutide:
Detailed Analysis
Commonalities
Epigen and Survodutide are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose Epigen for Recovery & Healing, Skin Health & Aesthetics. Choose Survodutide for Weight Loss, Liver Health.
Ready to Learn More?
Looking for trusted sources?